Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure

URN to cite this document:: urn:nbn:de:bvb:355-epub-269404
DOI to cite this document:: 10.5283/epub.26940

Braun, A. ; Ding, R. ; Seidel, C. ; Fies, T. ; Kurtz, Armin ; Schärer, K.

Preview

PDF
(505kB)

Date of publication of this fulltext: 11 Dec 2012 08:56

Alternative links to fulltext:Pubmed

Details

Preview

Export bibliographical data

Abstract

The single-dose pharmacokinetics of recombinant human erythropoietin (rHuEPO) given SC was investigated in 20 patients aged 7-20 years at different stages of chronic renal failure. In a pilot study we confirmed the lower bioavailability of the drug in 2 children when given SC compared with the IV route (24% and 43%, respectively). Following administration of 4,000 units/m2, rHuEPO SC effective ...